Home › Funds › Vestal Point Capital, LP › NBIX

Vestal Point Capital, LP position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

Vestal Point Capital, LP reported holding 1,880,000 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$316.8M, representing 7.40% of its reported portfolio and ranking #2 among its reported holdings. Vestal Point Capital, LP has disclosed NBIX holdings in 5 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)1.88M sh
Reported value held$316.85M
Portfolio Weight7.40%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's NBIX position evolved

Vestal Point Capital, LP first disclosed a stake in NBIX in Q4 2023 at 800,000 shares (US$105.4M). The position peaked in Q2 2026 at 1,880,000 shares, worth US$316.8M. Across 5 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,880,000 shares valued at US$316.8M — an increase of 630,000 shares quarter over quarter.. Notable position changes include a 50% increase in Q2 2026 (shares fell 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 800.00K $105.41M New
Q1 2024 710.00K $97.92M Reduce
Q2 2025 30.00K $3.77M New
Q1 2026 1.25M $164.68M New
Q2 2026 1.88M $316.85M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 33 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), RTW INVESTMENTS, LP (US$213.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has Vestal Point Capital, LP held NBIX?

Vestal Point Capital, LP has disclosed NBIX holdings in 5 of the last 11 reported quarters, going back to Q4 2023.

What is Vestal Point Capital, LP's current position in NBIX?

As of Q2 2026, Vestal Point Capital, LP holds 1.88M shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $316.85M, representing 7.40% of its reported portfolio and ranking #2.

Has Vestal Point Capital, LP been buying or selling NBIX?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in NBIX. The position peaked in Q2 2026 at 1.88M shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, RTW INVESTMENTS, LP, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.